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ABSTRACT
Introduction: The objective of this study was to
assess the effect of sitagliptin on insulin dose in
patients with inadequately controlled type 2
diabetes who titrate basal insulin to a target
fasting glucose level after initiating sitagliptin.
Methods: This was a multicenter, randomized,
double-blind, placebo-controlled, 24-week
clinical trial in which treatment with
sitagliptin 100 mg/day or placebo was
administered concurrently with insulin
glargine titration, targeting a fasting glucose of
4.0–5.6 mmol/L (72–100 mg/dL). The trial
randomized 660 patients with type 2 diabetes
and inadequate glycemic control on insulin,
with or without metformin (C1500 mg/day) or
sulfonylurea, for C10 weeks. Patients could
remain on metformin but not sulfonylurea
after randomization.
Results: The increase from baseline in the daily
dose of insulin was less in the sitagliptin group
(N = 329) compared to placebo (N = 329)
(between group difference = -4.7 IU [95%
confidence interval [CI] -8.3, -1.2];
p = 0.009). Patients in the sitagliptin group
had lower glycated hemoglobin (HbA1c) levels
after 24 weeks (between-group difference of
-0.4% [95% CI -0.6, -0.3; -4.9 mmol/mol
(95% CI -6.6, -3.2)]; p\0.001), and more
patients in the sitagliptin group reached the
HbA1c goal of \7.0% (53 mmol/mol), with a
between-group difference of 17.3% (95% CI
10.4%, 24.1%; p\0.001). Fewer patients in the
sitagliptin group experienced an adverse event
of hypoglycemia (between-group difference =
-15.5%, p\0.001).
Trial registration: ClinicalTrials.gov #NCT01462266.
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INTRODUCTION
Patients with type 2 diabetes typically
experience progressive deterioration in
glycemic control over time, which has been
primarily attributed to progressive loss of beta
cell function [1–3]. Consequently, most patients
will require intensification of therapy to
maintain glycemic control by the addition of
other antihyperglycemic agents to ongoing
treatment. Eventually, therapy with insulin is
required by many patients with type 2 diabetes.
Typically, basal insulin is used by patients with
type 2 diabetes initiating insulin therapy [4].
However, although insulin is the most
efficacious glucose-lowering agent currently
available, as many as 40–70% of patients
treated with insulin fail to achieve glycemic
goals [5–8]. This failure may have a number of
explanations, including patient and physician
factors, such as the occurrence or risk of
hypoglycemia, which limit aggressive titration
of insulin dose [9]. In addition, while treatment
with basal insulin targets fasting and pre-meal
blood glucose levels [4], the progressive
diminution in insulin secretory capacity in
patients with type 2 diabetes can lead to poor
post-prandial glycemic control, and as a result,
poor overall glycemic control.
Numerous studies have demonstrated
improved glycemic control when an oral agent
has been added to insulin therapy in patients
with type 2 diabetes [10–19]. However, these
studies have generally been performed in the
context of stable doses of insulin. The addition
of thiazolidinediones, metformin, or
sulfonylureas to ongoing therapy, in study
designs in which the dose of insulin was to
remain stable unless reductions were required
for hypoglycemia, has been shown to result in
reductions in insulin doses relative to the
addition of placebo [12, 14–18], presumably
related to more down-titration of insulin in the
active treatment groups. Similar observations
have not been made when dipeptidyl peptidase-
4 (DPP-4) inhibitors were added to ongoing
therapy with stable doses of insulin [10, 11, 13,
19]. In one study, Vilsbøll et al. [11] reported
that the addition of sitagliptin to ongoing
therapy with a stable dose of insulin (with or
without metformin) provided better glycemic
control after 24 weeks relative to a placebo [11].
However, in that study, the incidence of
hypoglycemia in the sitagliptin group (16%),
while lower than what has been observed in
similar studies with other DPP-4 inhibitors [10,
13, 19], was higher than that observed in the
placebo group (8%) [11].
The impact of the addition of a DPP-4
inhibitor to treatment of patients who are
actively up-titrating basal insulin using a
structured treatment algorithm targeting
fasting glucose has not been studied.
Sitagliptin lowers post-prandial glucose levels
by enhancing insulin secretion and by
suppressing glucagon production. It was
hypothesized that the addition of sitagliptin,
compared with a placebo, would result in
similar or better glycemic control with a lower
dose of insulin (i.e., would be ‘insulin-sparing’)
in patients with type 2 diabetes who are actively
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up-titrating the dose of basal insulin (with or
without metformin) to achieve target fasting




This was a multicenter, randomized, double-
blind, placebo-controlled clinical trial (Figure
S1) performed between January 16, 2012 and
June 07, 2013. The duration of the study was up
to 29 weeks, including a 1-week screening
period, a 2-week period for sulfonylurea wash-
off (for patients who were on sulfonylurea at the
screening visit) and/or insulin switch and
standardization (for patients who were not on
insulin glargine once daily in the evening)
(Table S1), a 2-week single-blind placebo run-
in period and a 24-week double-blind treatment
period, during which the starting insulin dose
was titrated based on pre-specified fasting
finger-stick glucose measurements starting
from Week 2 (Table 1), targeting a fasting
glucose of 4.0–5.6 mmol/L (72–100 mg/dL).
Patients were randomized (1:1) to sitagliptin
100 mg/day or placebo, and randomization was
stratified based on use of metformin and/or a
sulfonylurea at the screening visit.
Patients
Patients were eligible for the study if they were
18–80 years of age with type 2 diabetes. Patients
who were diagnosed with type 2 diabetes at or
after age 40 years were eligible if they had
insulin therapy initiated at least 3 years after
the diagnosis of diabetes. Patients diagnosed
before age 40 years, or patients diagnosed after
age 40 who had insulin initiated within 3 years
of diagnosis, were also eligible if they had
a fasting C-peptide (connecting-peptide) of
[0.7 ng/mL. Patients on a stable dose of
insulin glargine administered in the evening,
with or without metformin (C1500 mg/day) for
C10 weeks and with inadequate glycemic
control (defined as glycated hemoglobin
[HbA1c] C7.5% [58.5 mmol/mol] and B11.0%
[96.7 mmol/mol] at the screening visit) were
eligible to begin single-blind placebo run-in at
Week -2. Patients on a stable dose of insulin
(pre-mixed insulin, or basal insulin other than
insulin glargine given in the evening) with or
without metformin for C10 weeks, with HbA1c
C7.5% (58.5 mmol/mol) and B11.0%
(96.7 mmol/mol) at the screening visit were
eligible to begin single-blind placebo run-in
after a 2-week period to switch and stabilize
their insulin dose (to insulin glargine given in
the evening). Patients who were on a stable dose
Table 1 Insulin titration: patients were to adjust insulin dose as indicated based on three consecutive, daily (morning),
fasting ﬁnger-stick glucose measurements
Fasting glucose measurements Change in insulin glargine dose
[5.6 mmol/L (100 mg/dL) (on 3 consecutive mornings) Increase dose by 2 IU
[10.0 mmol/L (180 mg/dL) (on 3 consecutive mornings) Increase dose by 4 IU
B3.9 mmol/L (70 mg/dL) (at any time) Contact study physician for insulin dose (if study physician
not reached prior to next dose, dose reduced by 4 IU)
Goal was fasting glucose of 4.0–5.6 mmol/L (72–100 mg/dL)
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of premixed or basal insulin with or without
metformin for C10 weeks and were also
receiving a sulfonylurea, with HbA1c C7.5%
(58.5 mmol/mol) and B10.0% (85.8 mmol/mol)
at the screening visit were also eligible to begin
the single-blind placebo run-in after a 2-week
period to wash-off the sulfonylurea, switch to
insulin glargine and stabilize the dose if
necessary (i.e., for those who were not on
insulin glargine given in the evening). At the
start of the single-blind placebo run-in, all
patients were required to have FPG
C7.2 mmol/L (130 mg/dL) and B15.0 mmol/L
(270 mg/dL).
Patients were excluded from the study if they
had type 1 diabetes, a history of ketoacidosis,
active liver disease, significant and active
cardiovascular disease, malignancy,
hematological disorders or hyperthyroidism.
Patients were also excluded if they had been
treated with a DPP-4 inhibitor, a glucagon-like
peptide-1 receptor agonist or a
thiazolidinedione within the 12 weeks prior to
randomization. Patients were also excluded if
they were currently being treated with the daily
use of pre-prandial, short-acting or rapid-acting
insulin alone, or as part of a basal/bolus insulin
regimen. Patients with a history of two or more
episodes of hypoglycemia resulting in seizure,
coma, loss of consciousness, or with recurrent
(C3 times per week) episodes of hypoglycemia
during the 8 weeks preceding randomization
were also excluded.
Laboratory exclusion criteria included serum
creatinine C1.4 mg/dL (males) or C1.3 mg/dL
(females), an estimated glomerular filtration
rate \60 mL/min/1.73 m2 (calculated by
modification of diet in renal disease equation),
alanine aminotransferase or aspartate
aminotransferase [2 times the upper limit of
normal, hemoglobin\12 g/dL (male) or\11 g/
dL (female), triglycerides [600 mg/dL or
thyroid-stimulating hormone outside the
normal range.
Study Objectives
The primary objectives for the present study
were first to assess the effect of sitagliptin on the
change in insulin dose (in IU per day), when
compared with a placebo and second, to assess
the safety and tolerability of sitagliptin when
used in patients who are intensively titrating
basal insulin. The primary hypothesis of the
study was that after 24 weeks, sitagliptin
reduces the dose of insulin relative to a placebo.
Secondary objectives included the
assessment of the difference between the
effects of sitagliptin and placebo on change
from baseline in HbA1c, fasting plasma glucose
(FPG), body weight, the percentage of patients
who achieve the fasting glucose target of
4.0–5.6 mmol/L (72–100 mg/dL) and the time
it took to achieve this target.
Efficacy Endpoints
Efficacy endpoints included daily insulin dose
(reported in patients’ self-recorded finger-stick
glucose logs), laboratory assessment of HbA1c
and FPG, glycemic goal assessment (at or not at
goal, defined per protocol as 3 consecutive daily
fasting glucose measurements of 4.0–5.6 mmol/
L (72–100 mg/dL), obtained from patients’ self-
recorded finger-stick glucose logs), and a post
hoc analysis of the percentage of patients with
HbA1c \7.0% (53 mmol/mol) at Week 24 (or
the last visit prior to discontinuation).
Safety Measurements
Safety and tolerability were assessed through
the collection and analysis of adverse events
(AEs), vital signs, standard laboratory
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evaluations (including blood chemistry,
hematology, and urinalysis), body weight and
hypoglycemia assessment logs. All AEs were
rated by the study investigators for intensity
and relationship to study drug.
Symptomatic hypoglycemia was a pre-
specified AE of special interest. Any episode
with symptoms consistent with hypoglycemia
was reported as an episode of symptomatic
hypoglycemia without a requirement for
confirmatory blood glucose values and reported
as an AE. Episodes with no symptoms, but with a
measured blood glucose level of B3.9 mmol/L
(70 mg/dL), were reported as asymptomatic
hypoglycemia; these episodes could be reported
as AEs at the discretion of the investigator.
Episodes of hypoglycemia that required
assistance, either medical or non-medical, were
defined as severe hypoglycemia. Episodes with a
markedly depressed level of consciousness, loss
of consciousness, or seizure were classified as
having required medical assistance, whether or
not medical assistance was obtained.
Statistical Methods
The population for all efficacy analyses
consisted of all randomized patients who
received at least one dose of study medication
and had at least one measurement of the
analysis endpoint at or after baseline. The
statistical software used was SAS 9.3 (SAS
Institute Inc., Cary, NC, USA).
The primary efficacy endpoint, mean change
from baseline in daily insulin dose at Week 24,
was compared between the sitagliptin group
and the placebo group using a longitudinal data
analysis model [20] with a constraint that both
groups came from a single population with a
common baseline mean. The model adjusted
for the patients’ use of metformin at the
screening visit (i.e., on metformin, or not on
metformin). The model included the following
time points: Weeks 0, 2, 4, 6, 8, 10, 12, 15, 18,
21, and 24. Missing outcome data were handled
implicitly by the model without the need for
imputation. In the analysis model, the daily
insulin dose for any given week was defined as
the average dose from the three most recent
days preceding the index date for that week.
The continuous secondary endpoints of mean
change from baseline in HbA1c and FPG at week
24 were analyzed using a model analogous to
that for the primary endpoint, including the
time points of Weeks 0, 2 (for FPG only), 6, 12,
18, and 24. Statistical testing of between-group
differences for these secondary endpoints was
not pre-specified, but nominal p values (i.e.,
unadjusted for multiple comparisons) were
calculated. The planned sample size of the
study was 600 in total, to achieve 90% power
(2-sided, a = 0.05), to detect a difference of 6.8%
IU of daily insulin dose assuming a standard
deviation (SD) of 25 IU, or 9.5 IU assuming a SD
of 35 IU. The percentage of patients with HbA1c
\7% (53 mmol/mol) at Week 24 (or at the last
visit if a patient discontinued before Week 24)
were analyzed using the Miettinen and
Nurminen method [21] stratified by
metformin use at the screening visit. The time
to first attainment of fasting glucose target of
4.0–5.6 mmol/L (72–100 mg/dL) was analyzed
using the Kaplan–Meier method.
Analyses of safety data included all
randomized patients who received at least one
dose of study medication. The Miettinen and
Nurminen method [21] was used for between-
group comparisons of the percentage of patients
with safety endpoints. Calculation of a p value
for the between-group comparison for
symptomatic hypoglycemia was pre-specified.
The continuous safety endpoint of body weight
was analyzed using the same approach used for
the continuous efficacy endpoints.
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Statement of Ethics Compliance
The study (Sitagliptin Protocol 260;
ClinicalTrials.gov #NCT01462266) was
conducted in accordance with principles of
Good Clinical Practice and was approved by
the appropriate institutional review boards and
regulatory agencies. All procedures followed
were in accordance with the ethical standards
of the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
RESULTS
A total of 1217 patients were screened, and 557
patients were excluded (Figure S2), most
commonly for screen failure (45.3% not
meeting the Visit 1 HbA1c criteria or the Visit
1 insulin regimen criterion, and 29.4% for
exclusionary laboratory evaluation values). A
total of 660 patients were randomized to
double-blind treatment (Figure S2) with either
sitagliptin 100 mg once daily (330 patients) or
matching placebo (330 patients). Two
randomized patients who received no study
medication, one in each treatment group, were
excluded from all analyses. Of the 658 patients
who took at least one dose of study medication,
598 (90.6%) completed the trial, of whom 295
were in the sitagliptin group and 303 were in
the placebo group.
The baseline mean insulin dose in all treated
patients was 36.9 IU/day, mean HbA1c was
8.7% (71.6 mmol/mol), mean FPG was
9.8 mmol/L (176.5 mg/dL), and the mean
duration of diabetes was 13.5 years (range
1–33 years). Demographic and anthropometric
traits and baseline disease characteristics were
generally balanced between the treatment
groups (Table 2). Similar proportions of
patients in each treatment group had been
treated with sulfonylureas, or had been on pre-
mixed insulins, prior to randomization (data
not shown).
Change from Baseline in Insulin Dose
The mean insulin dose increased in both
treatment groups over 24 weeks, with most
of the increase occurring in the first 15 weeks
in both groups (Fig. 1a). In the test of the
primary study hypothesis, the change from
baseline in daily insulin dose after 24 weeks in
the sitagliptin group was significantly smaller
than that in the placebo group (p = 0.009;
Table 3).
Change from Baseline in Glycemic
Parameters
HbA1c
HbA1c levels decreased in both groups (Fig. 1b),
with greater reduction from baseline at Week 24
in the sitagliptin group relative to the placebo
group (between-group difference -0.4%
[-4.9 mmol/mol], p\0.001; Table 3). After
Week 12, the magnitude of the between-group
difference was similar throughout the
remainder of the trial.
FPG
At Week 24, reductions from baseline in FPG
were observed in both groups, with a larger
reduction in the sitagliptin group relative to the
placebo group (between-group difference
-0.6 mmol/L, p = 0.001; Table 3). FPG
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decreased in both groups through Week 18 with
an apparent plateau in both groups from Week
18 through Week 24 (Fig. 1c); a greater decrease
in the sitagliptin group was seen from the first
post-randomization measurement at Week 2
through the remainder of the trial.
Achievement of Glycemic Goal (HbA1c <7%
[53 mmol/mol])
In this post hoc analysis, the percentage of
patients with HbA1c \7.0% (53 mmol/mol) at
Table 2 Baseline demographic and anthropometric
characteristics
Parameter Sitagliptin Placebo
N5 329 N5 329
Age, years 59.3 ± 8.9 58.3 ± 9.7
Sex, male 151 (45.9) 164 (49.8)
Race
White 238 (72.3) 220 (66.9)
Multi-racial 36 (10.9) 54 (16.4)
Asian 32 (9.7) 34 (10.3)
Black 18 (5.5) 9 (2.7)
Native American or Alaska
Native
5 (1.5) 12 (3.6)
Ethnicity
Hispanic or Latino 86 (26.1) 84 (25.5)
Not Hispanic or Latino 234 (71.1) 237 (72.0)
Unknown 9 (2.7) 8 (2.4)
Body weight, kg 87.1 ± 19.5 88.3 ± 22.6
BMI, kg/m2 31.9 ± 5.8 32.2 ± 6.6
Duration of type 2 diabetes,
years
13.2 ± 6.0 13.7 ± 6.4
Prior metformin and sulfonylurea use
On metformin N = 285 N = 283
On sulfonylurea 90 (31.6) 94 (33.2)
Not on sulfonylurea 195 (68.4) 189 (66.8)
Not on metformin N = 44 N = 46
On sulfonylurea 5 (11.4) 6 (13.0)
Not on sulfonylurea 39 (88.6) 40 (87.0)
Data are expressed as mean ± standard deviation or
frequency (N [%]) unless otherwise indicated
BMI body mass index
A  Change in Daily Insulin Dose 
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Fig. 1 Efﬁcacy parameters over time. LS least squares, SE
standard error, HbA1c glycated hemoglobin, FPG fasting
plasma glucose, D difference. a Change in daily insulin
dose, b HbA1c, c FPG
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Week 24 (or the last visit prior to
discontinuation) was greater in the sitagliptin
group compared to the placebo group (Fig. 2).
The between-group difference was 17.3% ([95%
confidence interval [CI] 10.4%, 24.1%];
p\0.001).
Achievement of the Fasting Glucose Target;
4.0–5.6 mmol/L (72–100 mg/dL)
The Kaplan–Meier method was used to estimate
25th, 50th, and 75th percentiles of the time to
the first attainment of the fasting glucose target.
The percentiles were numerically shorter in the
sitagliptin group relative to the placebo group;
for example, the estimated 50th percentiles for
attaining the fasting glucose target were 78 days
(95% CI 64, 85) versus 90 days (95% CI 80, 107)
for sitagliptin and placebo, respectively
(Table 4).
The Kaplan–Meier estimate of the
cumulative percentage of patients who had
their first attainment of fasting glucose target
for each treatment group by Week 24 was
slightly higher in the sitagliptin group (77.4%,
[95% CI 72.6, 82.2]) relative to the placebo
group (74.1% [69.0, 79.2]). The between-group
difference in percentages was 3.3% (95% CI
-3.7, 10.3).
Table 3 Efﬁcacy endpoints
Parameter Sitagliptin, N5 329 Placebo, N5 329
Daily insulin dose, IU
Baseline 37.3 ± 20.8 36.6 ± 21.3
Week 24 54.8 ± 29.3 59.9 ± 31.9
Change from baseline* 19.0 (16.5, 21.6) 23.8 (21.3, 26.3)
Difference from placebo -4.7 (-8.3, -1.2) –
HbA1c, % (mmol/mol)
Baseline 8.7 ± 1.0 (71.2 ± 10.8) 8.8 ± 1.0 (72.8 ± 11.3)
Week 24 7.3 ± 1.1 (56.7 ± 11.8) 7.9 ± 1.2 (62.9 ± 13.3)
Change from baseline* -1.3 (-1.4, -1.2) (-14.3 [-15.6, -13.1]) -0.9 (-1.0, -0.8) (-9.5 [-10.7, -8.2])
Difference from placebo -0.4 (-0.6, -0.3) (-4.9 [-6.6, -3.2]) –
Fasting plasma glucose, mmol/L
Baseline 9.8 ± 2.6 9.8 ± 2.5
Week 24 6.7 ± 2.0 7.3 ± 2.4
Change from baseline -3.1 (-3.4, -2.8) -2.5 (-2.8, -2.2)
Difference from placebo -0.6 (-1.0, -0.2) –
Values are mean ± standard deviation unless noted
To convert fasting plasma glucose in mmol/L to mg/dL, multiply by 18
HbA1c glycated hemoglobin
* Least squares (LS) mean (95% conﬁdence interval (CI));  p = 0.009 vs placebo;  p B 0.001 vs placebo
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Safety
Incidences of AEs were similar between the two
treatmentgroups (Table 5). In the sitagliptin group,
64.7% of patients were reported to have any AE vs
69.9% in the placebo group and no notable
differences in the incidence of AEs by system
organ class were observed. A similar percentage of
patients in the sitagliptin group (4.0%) and in the
placebo group (3.6%) was reported to have serious
AEs (SAEs). No specific SAE term was reported in
more than one patient in either treatment group
and none of the SAEs were assessed by the
investigator as drug related. No patient in the
sitagliptin group discontinued study medication
due to an SAE while two patients in the placebo
group discontinued study medication due to an
SAE, one of acute myocardial infarction and the
other of cellulitis and sepsis.
The percentage of patients reporting at least
one AE of hypoglycemia, either symptomatic or
asymptomatic, was lower in the sitagliptin
group (28.3%) compared with the placebo
group (43.8%), with a between-group
difference of -15.5% ([95% CI -22.7, -8.2];
p\0.001) (Fig. 3). A significantly lower
percentage of patients in the sitagliptin group
experienced at least one AE of symptomatic
hypoglycemia compared with the placebo
group (25.2% vs. 36.8%; Fig. 3; p = 0.001); the
percentage of patients who reported recurrent
symptomatic hypoglycemia (3 or more
episodes) was lower in the sitagliptin group
(9.4% vs. 19.1%). A lower percentage of patients
in the sitagliptin group also reported at least
one AE of asymptomatic hypoglycemia
compared with the placebo group (9.1% vs.
16.1%; Fig. 3). Most episodes of hypoglycemia
in both treatment groups were mild or
moderate in intensity, and the percentage of
patients with at least one AE of severe
hypoglycemia was not meaningfully different
between treatment groups (3.0% sitagliptin vs.
4.0% placebo); (Fig. 3).
At Week 24, small increases in body weight
were observed in both treatment groups (0.6 kg
in the placebo group and 0.3 kg in the sitagliptin
group). The 95% CI around the between-group
difference of 0.3 kg was -0.8, 0.2.
DISCUSSION
In patients with type 2 diabetes who are not
achieving glycemic targets on one or more oral
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Fig. 2 Percentage of patients with HbA1c\7.0% (53 m-
mol/mol) at Week 24 or the time of discontinuation.
HbA1c glycated hemoglobin
Table 4 Kaplan–Meier estimated percentile of time (days) to ﬁrst attainment fasting glucose target
25th 50th (95% CI) 75th
Sitagliptin 37 78 (64, 85) 155
Placebo 45 90 (80, 107) 170
The fasting glucose target was deﬁned as three consecutive days with ﬁnger-stick fasting glucose of 4.0–5.6 mmol/L
(72–100 mg/dL)
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recommend the addition of a basal insulin [4].
While various algorithms for initiating and
intensifying basal insulin therapy have been
described and evaluated, they all share a
common strategy of dose adjustment based on
a targeted fasting blood glucose concentration
[5, 7, 8]. This strategy is effective in improving
glycemic control but many patients remain
above the HbA1c treatment goal of \7.0%
(53 mmol/mol) despite aggressive insulin
titration [5, 7, 8]. Further insulin titration may
be limited by the associated increased incidence
of hypoglycemia, which may cause substantial
health risks to patients. In a meta-analysis of 67
randomized clinical trials of insulin treatment
in type 2 diabetes patients, Pontiroli et al. [22]
found significant associations between the
incidence of hypoglycemia and both the
absolute reduction in HbA1c level and the
final achieved HbA1c level. In this context,
less stringent glycemic goals are recommended
for patients at increased risk for hypoglycemia.
For patients with type 2 diabetes who are
treated with insulin, reductions in total insulin
Table 5 Clinical adverse event (AE) summary




Difference in % vs. placebo
(95% CIb)
With one or more
AE 213 (64.7) 230 (69.9) -5.2 (-12.3, 2.0)
Drug-related AEa 48 (14.6) 73 (22.2) -7.6 (-13.5, -1.7)
Serious AE 13 (4.0) 12 (3.6) 0.3 (-2.8, 3.4)
Serious, drug-related AEa 0 (0.0) 0 (0.0) 0.0
Who died 2 (0.6) 1 (0.3) 0.3
Patients who discontinued
Due to AE 6 (1.8) 6 (1.8) 0.0 (-2.3, 2.3)
Due to drug-related AEa 4 (1.2) 2 (0.6) 0.6 (-1.1, 2.5)
Due to a serious AE 0 (0.0) 2 (0.6) -0.6
Due to serious drug-related AEa 0 (0.0) 0 (0.0) 0.0
Pre-speciﬁed AEs of interest
One or more
Adverse events of hypoglycemia 93 (28.3) 144 (43.8) -15.5 (-22.7, -8.2)
Asymptomatic 30 (9.1) 53 (16.1) -7.0 (-12.2, -1.9)
Symptomatic 83 (25.2) 121 (36.8) -11.6 (-18.5, -4.5)
Severec 10 (3.0) 13 (4.0) -0.9 (-4.0, 2.0)
CI conﬁdence interval
a Determined by the investigator to be related to the drug
b Computed using the method of Miettinen and Nurminen [21], and provided only for endpoints occurring in at least four
patients in one or both groups, per the pre-speciﬁed statistical analysis plan
c Protocol-speciﬁed deﬁnition of severe hypoglycemia: hypoglycemia requiring assistance, either medical or non-medical
136 Diabetes Ther (2015) 6:127–142
dose without sacrificing glycemic control may
be of clinical benefit. Higher insulin doses have
been associated with an increased risk of
hypoglycemia [23], and may also result in
greater weight gain [24]. While the use of oral
antihyperglycemic agents in combination with
insulin would be expected to lower total insulin
requirements, the impact of such combinations
on these other endpoints is of potential clinical
importance.
In the present study, patients titrating basal
insulin to a target fasting glucose level of
4.0–5.6 mmol/L (72–100 mg/dL) while being
treated with sitagliptin 100 mg/day, compared
with a similar group of patients titrating basal
insulin while being treated with placebo, had a
20% smaller increase from baseline in insulin
dose. Despite this smaller increase in insulin
dose (and a lower daily dose of insulin at Week
24), patients in the sitagliptin group had lower
HbA1c and FPG levels after 24 weeks, with a
higher percentage of patients at HbA1c goal of
\7.0% (53 mmol/mol).
As both treatment groups were instructed to
follow the same insulin titration algorithm, the
study was designed to achieve equipoise
between the two treatments with regard to
FPG levels. The mean FPG levels appeared to
plateau in both treatment groups by Week 18,
and[70% of patients in both treatment groups
achieved the protocol-specified FPG target of
4.0–5.6 mmol/L (72–100 mg/dL). Despite these
observations, which suggest that the study
duration and design were adequate to allow
for fasting glucose goal attainment, equipoise in
FPG between groups was not achieved at Week
24: the mean FPG level in the sitagliptin group
was lower than that in the placebo group.
Although sitagliptin has been shown to lower
FPG in both insulin-treated and non-insulin-
treated patients [25–28], this finding was
unexpected in this study, as the
superimposition of an insulin titration
algorithm was expected to compensate for the
lack of the effect of sitagliptin in the placebo
group. The reason for this lack of equipoise on
FPG is not clear. One possible explanation is
that the higher incidence of hypoglycemia in
the placebo group may have limited the ability
to titrate insulin sufficiently or to maintain the
insulin dose at the maximally titrated level,
although this study was not designed to
evaluate the impact of hypoglycemia on
titration of insulin. Another possibility is
clinical inertia in both treatment groups that
resulted in the sitagliptin group having better
glycemic control (including a lower mean FPG)
due to the additional antihyperglycemic
medication. Regarding the differences
observed in HbA1c reduction between groups,
the greater reduction in post-meal glucose levels
in the sitagliptin group may have also
contributed to the greater improvement in
HbA1c. In keeping with the improved
glycemic control achieved in both groups in
this study, and possibly due to the titration of
insulin, the percentage of patients with an
HbA1c \7.0% (53 mmol/mol) at week 24 was
more than twice that observed in previous
Δ = -11.6
(-18.5, -4.5)








































Fig. 3 Percentage of patients reporting an adverse event of
hypoglycemia. Differences are for sitagliptin minus place-
bo, with 95% conﬁdence intervals. D difference
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studies in which a DPP-4 inhibitor was added to
ongoing stable insulin therapy [10, 11].
Improvement in glycemic control with
insulin is typically associated with an increase
in the incidence of hypoglycemia. Additionally,
previous studies have reported that the
incidence of hypoglycemia when an oral agent
is combined with insulin is either similar [13,
14, 18–22], or higher [16, 17, 19] compared to
the combination of placebo with insulin.
Uniquely, in the current study, greater
improvement in glycemic control with
sitagliptin added on to insulin occurred along
with a significantly lower incidence of
symptomatic hypoglycemia relative to placebo
(25.2% vs. 36.8%), representing a relative
reduction of 32% for the sitagliptin group
compared to the placebo group.
The lower incidence of hypoglycemia in the
sitagliptin group in the current study may be a
consequence of the lower dose of insulin used
in this group throughout the duration of the
trial. Other potential explanations for the lower
incidence of hypoglycemia in the sitagliptin
group, such as improved counter-regulation in
response to hypoglycemia, cannot be excluded,
although altered counter-regulation has not
been observed with DPP-4 inhibitor treatment.
However, it is of interest that the levels of the
incretin hormone glucose-dependent-
insulinotropic polypeptide (GIP) have been
demonstrated to augment glucagon secretion
in the setting of hypoglycemia [29–31].
Investigation of the role of stabilization of
active GIP by sitagliptin in altering the risk of
hypoglycemia will be of interest.
The incidences of hypoglycemia in both the
sitagliptin and placebo groups were higher in
this study compared to a previous study of
sitagliptin added onto stable-dose insulin
treatment [11]. However, a cross-study
comparison is not appropriate because of the
differences in the management of insulin doses
between the two studies. In the previous study,
sitagliptin was added to ongoing insulin
treatment and the insulin dose was kept stable
(except for down-titration for hypoglycemia,
doses were maintained within 10% of the
baseline dose) for the duration of the study [22].
Despite an increase from baseline in the dose
of insulin in the sitagliptin group, a minimal
increase in weight occurred in this group. The
mean change from baseline in body weight of
0.3 kg at Week 24 observed in this study was
within the range of the mean change from
baseline in body weight observed at Week 24 in
studies where a DPP-4 inhibitor was added to
stable doses of ongoing insulin therapy [10, 11,
13, 19] despite a greater daily dose of insulin
and reduction in HbA1c in this study than in
the previous studies.
The results of the current study are
consistent with observations made in two
recent open-label studies in which sitagliptin
was combined with insulin [32, 33]. An open-
label, randomized, active comparator
controlled, 24-week trial in Korea [32]
examined the efficacy and safety of adding
sitagliptin to ongoing insulin therapy
compared to up-titration of insulin; patients
were allowed to remain on stable doses of other
antihyperglycemic agents, including
sulfonylureas. Compared with up-titration of
insulin alone, sitagliptin treatment added to
ongoing insulin therapy resulted in a greater
decrease in HbA1c and a lower incidence of
symptomatic hypoglycemia, even though there
was a reduction in the insulin dose. Despite
differences in study design, and differing
definitions of hypoglycemia, the overall results
from our study are consistent with the results
from the study in Korean patients [32].
Similarly, an open-label, randomized study of
sitagliptin- and metformin-treated patients
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initiating a twice-daily biphasic insulin while
continuing or discontinuing sitagliptin revealed
significantly greater reductions in HbA1c and a
trend towards lower rates of hypoglycemia, in
patients continuing sitagliptin therapy [33].
The limitations of this study include the fact
that the study may not have been of sufficient
duration to observe the full effect of insulin
titration, as insulin doses had not plateaued by
Week 24. Additionally, the full impact of the
intervention on asymptomatic hypoglycemia
and nocturnal hypoglycemia is difficult to
assess in the absence of continuous glucose
monitoring. Despite these limitations, the
results from this study will be useful to guide
the treatment of patients who are on basal
insulin and wish to titrate their insulin doses
based on fasting glucose values.
CONCLUSIONS
The ability to achieve glycemic treatment
targets with insulin may be limited by the
occurrence of hypoglycemia during insulin
titration. As demonstrated in this study, the
concurrent administration of sitagliptin with a
treat-to-target insulin titration regimen reduced
the insulin dose requirement while providing
superior glycemic efficacy and a reduced
incidence of hypoglycemia compared to the
treat-to-target insulin-only titration regimen.
This study is the first to reflect clinical practice
more accurately as to how the combination of a
DPP-4 inhibitor and basal insulin is typically
administered: a stable dose of the DPP-4
inhibitor and a titration of the basal insulin to
fasting glucose target. The data suggest that the
addition of the DPP-4 inhibitor sitagliptin may
allow for more efficient and safer titration of
basal insulin, thus bringing more patients to
glycemic target with less risk of hypoglycemia.
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